Member Info for The.Italian

morning heimdal.happy new year to you also.yes interesting post.i do have the faintest of hopes that one day someone will see regent as a means of gaining main market access. tbh its really just a fantasy hope as i don't expect it to happen in reality.perhaps it was more likely when our market cap was at its lowest (about£16m?) but now we are at about £42m it's even less likely. no idea what the average market cap is for main market listed companies on the HK exchange but i imagine we are towards the bottom end.anyway good to know that the expectation is that the market should have a better year.fingers crossed.

morning Odysseus. yes good names all. only need Scylla andCharybdis for the set.ive put you down as Charon of course! Veuve Clicquot would be most acceptable and i am happy to return your good wishes for NYE and 2021.

morning bucolic.yep fraid so.nice to see a modest rise. happpy new year to you and GLA

pi and rho Bruce, easily mixed up!

hello odysseus. yes I'm happy with that. good to know your education hasn't been wasted. personally i both think and type very slowly, as i find it helps to pass the time. occasionally it produces some strange results. today i was trying to send a post referring to Ronnie Corbett (don't ask me why).it came out and was posted as "Ronde Corset". i found this absolutely hilarious, which i suppose just demonstrates i should get out more.(and if the punctuation police are out, apologies for not bothering with any capital letters).thanks for the explanation of "typo"by the way. i had always thought it meant a novice or inexperienced person, probably the result of my classical education, getting my pis mixed up with my rhos. happy new year to you all!

rationale?

agreed bucolic.my sentiments entirely.gla and HNY to you.

morning bucolic.i have a gap in posts between dec23rd and yesterday morning.i haven't been posting personally as just waiting developments and although I've been reading the board I'm not sure what posts are missing.

afternoon bignose.i certainly can't disagree with the general sentiments of your main post.i do have perhaps a different take on the longevity aspect,not because i want regent to lessen its focus on fortacin, as i certainly don't, but because i worry the mellon has lost interest in it and until we know whether the OTC switch is going to generate sales we have the spectre of poor take up hanging over us.so i see longevity as hopefully a beneficial diversification,which i hope won't distract too much from fortacin.i doubt that the original regent personnel are going to have that much input into it, as i suspect it will be driven,if at all,by Zhavaronkov,although that obviously is just speculation.i am pleased that the option has been taken up although i don't suppose it was ever in doubt ,as it does suggest positivity re the FDA aspect which i think we both agree is critical to fortacin's success.like you I've had to cut back a bit on my aspirations here and have not renewed the lease on my grain silo. however i have kept a small shoebox from a christmas present which I'm hoping will prove totally insufficient for the ultimate bounty which i am expecting here. best wishes to you and all on here for 2021!

bignose once again thank to you and pom for the dli update.no i don't imagine this is going to produce any meaningful revenue, but at this stage of its development i don't really expect dli to be revenue positive I'm afraid.i expect them to be concentrating on developing product awareness and professional acceptance of the ageing clock technology.i think they see the ultimate primary revenue source as coming from the life insurance and actuarial industries and professions,,as well as assisting with drug development trials. this will be their focus and so need to develop product awareness and acceptance.the young ai app is perhaps an attempt to find a modest revenue source whilst they concentrate on the long term aim of professional.i accept that lack of revenue will continue to be a problem and i expect further found raising to address this I'm afraid.however i tend to look at the longevity field as a whole of whichDLIis a very small part.i won't recite the detail as its quite labyrinthine, but there is a significant degree of interconnectivity between the various players in this area.mellon is interested in juvenescence, juvenescence is interested in insilico and insilico is interested in DLI. insilco uses its proprietary AI platform to discover novel targets for anti ageing drugs before handing them over to juvenesece for clinical research. if my arithmetic is correct insilco either directly or indirectly through its officers or key personnel owns over 10% of regent (this is insilco in its various corporate incarnations, Zhavoronkov Polina Mamoshima and a couple of other Insilico insiders). mellon repeatedly states his intention to IPO juvenescence,albeit probably in the US.Zhavoronkov stated in april that he hoped to ipo insilco in a couple of years ,probably in hong kong or shanghai. now none of this may ever happen, or if it does it may not involve regent or DLI in any way, but to least it strikes me as an area with significant potential and one in which it may eventually prove very beneficial for Regent to be involved. dilution has been and will continue to be a major problem,no denying that ,but at least i feel there is something here which may ultimately be quite valuable.just my opinion and probably simplistic and overly optimistic.

afternoon/evening bignose.i see what you mean but tbh i didn't even notice the use of "attempted".i agree its perhaps not the best choice of words but it doesn't sound as though its a failed"attempt"i suspect its written by someone for whom english is not the first language,although i could be wrong.its christmas so I'm putting it down to that,but who knows.hope this post makes sense as I've been on the pre lunch champagne.lets see what 2021 brings.now for the turkey.merry christmas!

Hi there!
Earlier this December we launched the Longevity Medicine course on Udemy and LabXchange.

Together with experts such as Evelyne Yehudit Bischof, MD, Dr. Alexey Moskalev, PhD, and Dr. Morten Scheibye-Knudsen, MD, PhD, we attempted to deliver an Introduction to Longevity Medicine as the most exciting and rapidly growing area of science and medicine.

Since then, over 750 learners registered on Udemy with 128 ratings totaling 4.5*. Together with the LabXchange course - that is about 1,000 learners in under one month!

If you haven’t tried it yet - the time is now!

Here is the link to register for the course for free during the next 3 days (there is no time cap for completion).

The coupon code is: 6358211CDFAF0BD00A86

If you have already passed the course, forward this link to your friends and colleagues, because knowledge, optimistic attitude to life and longevity make a great holiday gift. Millionaires pay a lot of money to learn the secrets of longer life. Now it is free to everyone.

Of course, we are not going to stop. The team is now working on a series of advanced courses.

Share your feedback on education platforms and suggest topics you might have missed in the current course. We would really appreciate it!

Best regards and happy holidays,
Mary

Let's Get Started
buon Natale all! just thought id share the latest email from deep longevity received this morning.not saying its particularly significant but i like the enthusiasm and self promotion,very essential in a start up.have a good christmas one and all!

buon Natale everyone!

morning bothwell.i can assure you i am quite unique,although not necessarily in a positive way.interesting thought though, if a bit odd.

pay no attention to the ostensible sells v buys figures. all to do with time of reporting/delayed trades etc.no one can seriously believe that if the ratio were as stated the s/p would go up by 11%

very impressive imo!

and merry christmas to you Albert and LF.stay safe and stay positive!

excellent find LF.most of the technical stuff goes over my head but i can form an impression of the overall significance of what is happening.very very encouraging.good find

absolutely dead cross.i also agree entirely with the first point in bonkers's 15.10 post .for me the o2 deal demonstrated confidence from a major telecom player.i bought in again having been out since 2018 on the back of the o2 deal. i never really expected the deal to produce much in the way of revenue,as the product was still in its infancy, but it's the confidence level from that and now particularly today's announcement which provides the investment case for me.

agreed dead cross.it was the contract length which stood out for me.excellent news all round of course.